Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

What are Viruses?00:50

What are Viruses?

128.1K
Overview
128.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

5.9K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
Chronic Pharyngitis01:23

Chronic Pharyngitis

11.9K
Chronic pharyngitis refers to persistent inflammation of the pharyngial mucosa.
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
11.9K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

583
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
583

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.

The Lancet. Microbe·2026
Same author

Prospective multicentre study of upper respiratory mucosal transcriptomics reveals two major endotypes of critically ill COVID-19 patients.

Communications medicine·2026
Same author

Indeterminate Phase/Grey Zone of Chronic Hepatitis B: Clinical Features, Outcomes and Molecular Insights.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Hepatitis C virus elimination: So close, so far?

Antiviral research·2026
Same author

Hepatitis D Virus Seroconversion Rate Among People With Chronic Hepatitis B Virus Infection in France and The Gambia (Inci-D).

Open forum infectious diseases·2026

Video Experimental Relacionado

Updated: Feb 1, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Infección crónica por el virus de la hepatitis B

Wai-Kay Seto1, Ying-Ru Lo2, Jean-Michel Pawlotsky3

  • 1Department of Medicine, The University of Hong Kong Queen Mary Hospital, Hong Kong Special Administrative Region, China; Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China; State Key Laboratory for Liver Research, The University of Hong Kong, Hong Kong Special Administrative Region, China.

Lancet (London, England)
|November 30, 2018
PubMed
Resumen

La infección por el virus de la hepatitis B representa un riesgo para la salud mundial, pero la vacunación y las terapias efectivas reducen significativamente el transporte crónico y la progresión de la enfermedad. La optimización de la gestión y el desarrollo de nuevos tratamientos son clave para su eliminación para 2030.

Más Videos Relacionados

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Videos de Experimentos Relacionados

Last Updated: Feb 1, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.1K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Área de la Ciencia:

  • Hepatología
  • Virología
  • Salud pública

Sus antecedentes:

  • La infección crónica por el virus de la hepatitis B (VHB) es un gran problema de salud mundial, que conduce a importantes enfermedades y muertes relacionadas con el hígado.
  • La transmisión ocurre al nacer o a través del contacto de persona a persona, lo que pone de relieve la importancia de las medidas preventivas.
  • Los niveles elevados de ADN del VHB son un factor de riesgo primario para la progresión de la enfermedad en individuos infectados crónicamente.

Objetivo del estudio:

  • Revisar el panorama actual de la gestión de la infección por el virus de la hepatitis B.
  • Para resaltar los avances en diagnósticos, terapias y estrategias de prevención.
  • Evaluar la viabilidad del objetivo de la Organización Mundial de la Salud de eliminar el VHB para 2030.

Principales métodos:

  • Revisión de la literatura existente sobre epidemiología, patogénesis y tratamiento del virus de la hepatitis B.
  • Análisis de las herramientas actuales de diagnóstico y seguimiento, incluida la evaluación no invasiva de la fibrosis.
  • Evaluación de la eficacia y la seguridad de las terapias nucleoanalógicas.
  • Evaluación de nuevos agentes terapéuticos en desarrollo.

Principales resultados:

  • La vacunación es muy eficaz para prevenir la infección por el VHB y su transmisión crónica.
  • La terapia con nucleótido análogo ofrece una supresión viral segura y efectiva, reduciendo las complicaciones hepáticas.
  • La evaluación no invasiva de la fibrosis es una herramienta emergente e importante junto con los métodos tradicionales.
  • Se están desarrollando nuevas terapias prometedoras, que ofrecen opciones de tratamiento en el futuro.

Conclusiones:

  • Las estrategias de manejo efectivas, incluida la vacunación, las terapias antivirales potentes y la mejora de la vinculación de la atención, son cruciales para controlar la infección crónica por VHB.
  • El objetivo de eliminar el virus de la hepatitis B como una amenaza para la salud mundial para 2030 es alcanzable con avances continuos y esfuerzos globales.